| Date Filed | Type | Description |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 10/12/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/23/2023 |
4
| Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Bought 27,000 shares
@ $1.2658, valued at
$34.2k
|
|
| 08/16/2023 |
4
| Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Bought 2,750 shares
@ $1.798, valued at
$4.9k
|
|
| 08/10/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/09/2023 |
4
| Cockroft Bettina M. (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 8,300 options to buy
@ $1.67, valued at
$13.9k
|
|
| 05/09/2023 |
3
| Cockroft Bettina M. (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc. |
| 05/01/2023 |
4
| Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Exercised 1,250 restricted stock units
@ $0 |
|
| 05/01/2023 |
4
| Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Exercised 521 restricted stock units
@ $0 |
|
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/31/2023 |
4
| Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 16,467 restricted stock units
@ $0 |
|
| 03/31/2023 |
4
| Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 6,067 restricted stock units
@ $0 |
|
| 01/04/2023 |
4
| Charles Faith L. (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 3,500 options to buy
@ $2.4, valued at
$8.4k
|
|
| 01/04/2023 |
3
| Charles Faith L. (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc. |
| 04/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/14/2022 |
4
| Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 33,000 shares
@ $0.31, valued at
$10.2k
|
|
| 03/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/09/2022 |
4
| Evans Carl Anthony (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 3,750 shares
@ $0.268, valued at
$1k
|
|
| 03/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/25/2022 |
4
| Priebe Waldemar (10% Owner) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Disposed of 1,495,867 shares
@ $0 |
|
| 12/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/22/2021 |
4
| Downs Christopher (CFO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Bought 4,500 shares
@ $1.1537, valued at
$5.2k
|
|
| 11/18/2021 |
4
| Climaco John M (CEO) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 5,000 shares
@ $1.28, valued at
$6.4k
|
|
| 07/16/2021 |
4
| Andraczke Andrzej (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 32,000 options to buy
@ $1.8, valued at
$57.6k
|
|
| 07/16/2021 |
4
| Gumulka Jerzy (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.|
Txns:
| Granted 32,000 options to buy
@ $1.8, valued at
$57.6k
|
|
|